Injury minimization after myocardial infarction: focus on extracellular vesicles

Area of Science:

• Regenerative Medicine
• Cardiovascular Biology
• Biotechnology

Background:

• Acute myocardial infarction (AMI) still has high mortality, particularly in patients with low left ventricular ejection fraction (LVEF).
• Existing cell therapies for cardiac repair show limited success, necessitating novel cardioprotective strategies.
• Extracellular vesicles (EVs) are emerging as a promising cell-mimetic therapy for cardiovascular diseases.

Purpose of the Study:

• To review the translational potential of extracellular vesicle (EV)-based therapies for cardioprotection after myocardial infarction.
• To highlight findings from large-animal studies evaluating EV efficacy and safety.
• To summarize ongoing early-stage clinical trials of EV therapies in cardiology.

Main Methods:

• Review of preclinical data, focusing on large-animal models of myocardial infarction.
• Analysis of the biological properties of EVs, including their cargo and paracrine mechanisms.
• Synopsis of current clinical trial landscape for EV-based cardiac therapies.

Main Results:

• EVs, derived from mesenchymal and cardiac stromal progenitor cells, demonstrate safety and efficacy in preclinical settings.
• EVs offer clinical advantages over cell therapy, including stability, storage potential, and reduced immunogenicity.
• Large-animal studies support the therapeutic potential of EVs for cardiac repair post-infarction.

Conclusions:

• EV-based therapies represent a promising advancement in regenerative medicine for treating myocardial infarction.
• The unique properties of EVs facilitate their development into 'off-the-shelf' therapeutic products.
• Ongoing clinical trials are crucial for validating the efficacy and safety of EV therapies in human patients.